Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
:GPCR
RESEARCH TOOLSreports
GPCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.22 - $62.74
Previous CloseN/A
Volume219.80K
Average Volume (3M)988.71K
Market Cap
$1.41B
Enterprise ValueN/A
Total Cash (Recent Filing)$883.52M
Total Debt (Recent Filing)$3.86M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 07, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding57,536,750
10 Day Avg. Volume634,902
30 Day Avg. Volume988,714
Financial Highlights & Ratios
PEG Ratio2.93
Price to Book (P/B)4.37
Price to Sales (P/S)0.00
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$81.44Price Target Upside231.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Structure Therapeutics, Inc. Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAleniglipron's similar but slightly different structural properties makes it unique and differentiated, which might be important to see a differentiated weight loss results in the ACCESS trials.
Competitive AdvantagePfizer discontinuing development of their oral small molecule GLP-1R agonist, danuglipron, reduces near-term competition for aleniglipron.
Financial StabilityManagement reported a cash balance of $836.9M, which is expected to fund operations through at least 2027.
Bears Say
Competitive PositioningAn important consideration for oral obesity treatments is how Lilly will position orforglipron alongside tirzepatide and whether oral GLP-1 therapies can carve out a meaningful role given the entrenched dominance of injectable formulations.
Market ChallengesPharmacy benefit manager (PBM) access remains a challenge for incremental entrants in this space.
Ownership Overview
11.67% Insiders
35.25% Mutual Funds
43.64% Other Institutional Investors
8.43% Public Companies and Individual Investors
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $62.74 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.41B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 07, 2025 which is in 71 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 08, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.246 by -$0.024.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.27.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,536,750 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.246. Following the earnings report the stock price went down -4.661%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.44 (231.73% Upside)
$81.44 (231.73% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 993.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.61%
12-Months-Change
Fundamentals
Return on Equity
-22.88%
Trailing 12-Months
Asset Growth
89.53%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$81.44
▲(231.73%Upside)
Technical Analysis
Wave Life Sciences
―
89bio
―
Enliven Therapeutics
―
Nurix Therapeutics
―
Dyne Therapeutics
―